Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 dose-ranging placebo-controlled study in moderate to severe plaque psoriasis
2009-013037-19Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VB-201 in plaque psoriasis (3 arms), sponsored by VBL Therapeutics. Primary endpoint: PASI 75 response at Week 12. Started Oct 2009; status: completed.
02
Drugs
VB-201
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2009-013037-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013037-19.